Responses
Extended report
Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis
Compose a Response to This Article
Other responses
Jump to comment:
- Published on: 13 April 2016
- Published on: 13 April 2016About “Scleroderma lung study"Show More
Dear Sir,
We have read the interesting paper of Clements PJ et al (1) as well as their previous article “Cyclophosphamide versus placebo in scleroderma lung disease” (2).
We think the Authors should give information about the autoantibody status of the patients; the recent analysis of the very large EUSTAR cohort of scleroderma cases demonstrated that autoantibody specificity is more closely related to or...
Conflict of Interest:
None declared.